Lumos Diagnostics Holdings Limited (ASX:LDX)

91.0¢

right-arrow Created with Sketch. 0 (0%)
MCAP $136.8M
Last trade 16.12pm 03/12/2021 20mins delayed

Latest Announcements

18/11/2021LDXLumos Diagnostics Holdings Limited
11/11/2021LDXLumos Diagnostics Holdings Limited
03/11/2021 Price SensitivePSLDXLumos Diagnostics Holdings Limited
28/10/2021LDXLumos Diagnostics Holdings Limited
28/10/2021LDXLumos Diagnostics Holdings Limited
28/10/2021LDXLumos Diagnostics Holdings Limited
28/10/2021LDXLumos Diagnostics Holdings Limited
28/10/2021LDXLumos Diagnostics Holdings Limited

Company Overview

Lumos Diagnostics Holdings Limited (Lumos) is an Australia-based company that develops, manufactures and commercializes point-on-care (POC) diagnostic test solutions. The Company's solutions help healthcare professionals to accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and digital reader platforms. The Company's portfolio of product, technology and service offerings include Point-of-care diagnostic products, Point-of-care readers, Commercial services and Manufacturing services. The Company's products include FebriDx and CoviDx. FebriDx is an all-in-one point-of-care test device that can differentiate a viral from bacterial acute respiratory infection. CoviDx is a rapid immunoassay for the detection of the nucleocapsid protein in nasal swabs (NS), oropharyngeal swabs (OP), and nasopharyngeal swabs (NP) from patients suspected of a Coronavirus-19 (COVID-19) infection.

LDX in the news

Lumos Diagnostics (LDX) receives authorisation to sell its COVID-19 rapid diagnostic test…
Shares in Lumos Diagnostics (LDX) dip this morning after the company retracts…
Shares in Lumos Diagnostics (LDX) slump after the FDA deprioritised an application…
Lumos Diagnostics (LDX) will begin trading on the ASX in July following…

Search Previous Announcements